UAE-FED-NATIONAL-COUNCIL
9.1.2019 19:16:14 CET | Business Wire | Press release
His Excellency Antonio Tajani, President of the European Parliament, expressed his deep appreciation for the UAE’s global humanitarian and relief efforts, manifested through the work of the Emirates Red Crescent and described them as “really impressive”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190109005738/en/
His statement came during a brief speech delivered on Tuesday, January 8, 2019, during the opening of the three-day ‘Humanitarian Aid for Stability’ exhibition at the European Parliament in Brussels, Belgium. The event was organized by the Emirates Red Crescent in coordination with the Federal National Council (FNC), the parliamentary body of the UAE.
The opening of the exhibition drew the participation of Her Excellency Dr Amal Al Qubaisi, Speaker of FNC, His Excellency Fahad Abdelrahman Bin Sultan, Deputy Secretary General for International Aid at the Emirates Red Crescent, members of the European Parliament, and several ambassadors.
His Excellency Antonio Tajani called for joint action between the UAE and Europe to deal with illegal immigration, expand cooperation in this regard to the Middle East and Africa, and strengthen collaborative efforts to combat terrorism and enhance security. He added that ensuring stability and promoting development efforts in the world are common goals for the UAE and the EU.
His Excellency Antonio Tajani stressed that the refugee crisis is a global challenge, and therefore humanitarian aid must be a collective task that engages nations and peoples.
Furthermore, he thanked Antonio López-Istúriz White, Secretary General of the European People’s Party and member of the European Parliament, for his initiative in holding the exhibition that presented a novel opportunity to showcase the endeavors of valued partners of the EU to help alleviate the devastating effects of war. He added that war and natural disasters are the reasons for thousands of migrants trying to seek refuge in Europe.
His Excellency Antonio Tajani said: “The exhibition carries the positive message of hope. Yes, hope, because helping each other, providing a roof for people in need is providing hope, and hope is the fuel for a better tomorrow.”
In closing, he invited guests to view the exhibition that included a model of the Mrajeeb Al Fhood camp for Syrian refugees in Jordan and an interactive world map of areas in which the Emirates Red Crescent operates. He also highlighted the EU’s humanitarian commitment to helping refugees that places it at the forefront of humanitarian aid providers globally, and called for reinstating stability and security in the refugees’ home countries to overcome this global challenge.
Speaking on the sidelines of the launch of the exhibition, His Excellency Fahad Abdelrahman Bin Sultan said: “The humanitarian and development aid offered by the UAE to the world amounted to US$32.01 billion from 2013 to 2017 and benefited millions of people across the globe, including 10 million Yemenis.”
He added: “This exhibition is the first of its kind outside the UAE and was organized at the request of the European Parliament to explore the UAE’s international humanitarian, relief, and development role that is based on the country’s noble values and enhances the global humanitarian ecosystem.”
His Excellency Fahad Abdelrahman Bin Sultan stressed that the UAE humanitarian and development aid focuses on meeting the needs of refugees and displaced civilians in volatile areas, such as Syria, Yemen, Somalia, Palestine, Afghanistan, and Iraq. He pointed out that the UAE has gained international respect and trust, and placed first globally for the fifth consecutive year for its contribution of humanitarian and development aid relative to national GDP.
He noted that more than 100 countries have benefited from aid provided by the UAE, adding that the Emirates Red Crescent has 14 offices in countries such as Yemen, Somalia, Kazakhstan, Indonesia, Pakistan, Afghanistan, Bosnia, and Albania.
His Excellency Fahad Abdelrahman Bin Sultan outlined the distribution of the UAE humanitarian aid as follows: US$4.92 billion to Yemen from April 2015 to December 2018, around US$174.6 million to Libya from 2013 to 2017, around US$963.5 million to the Syrian people from 2012 to November 2018, around US$641.5 million to the people of Erbil (Iraq) from 2013 to 2017, around US$233.3 million to Somalia from 2013 to 2017, US$489 million to Palestinians from 2013 to 2018, and US$333.3 million to Afghanistan from 2013 to 2017.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005738/en/
Contact:
Federal National Council, United Arab Emirates : Mohammed Al-Sawafi, +971506183874 m.alsawwafi@almajles.gov.ae Twitter: @FNC_UAE
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
